Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RELMADA THERAPEUTICS, INC. Director's Dealing 2021

Jan 27, 2021

34465_dirs_2021-01-27_c7a4c7ad-4bed-4701-9db5-512fadb7140c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-01-22

Reporting Person: Shenouda Maged (CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-22 Common Stock M 4000 $3.24 Acquired 6228 Direct